育龄期妇女慢性乙型肝炎诊治管理及母婴阻断策略

韩国荣

doi:10.3969/j.issn.1001-5256.2019.07.001

育龄期妇女慢性乙型肝炎诊治管理及母婴阻断策略

DOI: 10.3969/j.issn.1001-5256.2019.07.001

韩国荣

南京中医药大学附属南京医院南京市第二医院妇产科

基金项目:

十三五重大专项(2017ZX10201201-002-001,2017ZX10201201-001-002)；

详细信息

中图分类号: R714.251
计量
- 文章访问数: 1334
- HTML全文浏览量: 31
- PDF下载量: 434
- 被引次数: 0
出版历程
- 收稿日期: 2019-04-25
- 出版日期: 2019-07-20

Diagnosis and treatment of chronic hepatitis B in women of child-bearing age and strategies for blocking mother-to-child transmission

Han GuoRong

Department of Gynecology and Obstetrics, The Affiliated Nanjing Hospital of Nanjing University of Chinese Medicine &Nanjing Second Hospital

Research funding:

摘要

摘要: 慢性HBV感染者妊娠面临母婴两方面的问题,一是防治孕期肝炎活动,二是阻断母婴传播。对于HBeAg阳性母亲,出生不及时行联合免疫,婴儿的慢性HBV感染率高达90%。新生儿采用主动和被动联合免疫是预防HBV母婴传播安全而有效的措施,但是尽管采取了联合免疫,HBeAg阳性孕妇所生的婴儿仍有5%～10%感染HBV。妊娠期免疫系统变化,增加HBV复制,分娩后免疫系统激活,可致肝功能波动及慢性乙型肝炎患者病情加重,婴儿免疫失败则成为儿童及成人慢性乙型肝炎的源头。因此,对这部分特殊人群即HBV慢性感染育龄期妇女,特定的检测、干预及随访措施尤其值得关注和探讨。讨论了如何对育龄HBV感染的妇女进行整体系统的孕前、孕期及产后的管理,对孕妇及婴儿有效监测,通过疾病风险评估根据个体情况得到个体化的精确治疗,并对准备生育的慢性乙型肝炎感染者进行生殖和健康指导。
- 肝炎,乙型,慢性 /
- 肝炎病毒,乙型 /
- 妊娠 /
- 孕妇
Abstract: Women with chronic hepatitis B virus ( HBV) infection face both maternal and child problems during pregnancy. One problem is to prevent hepatitis activities during pregnancy, and the other is to block mother-to-child transmission. Infants born to HBeAg-positive mothers may have a rate of chronic HBV infection of 90% if they do not receive combined immunization in time. The combination of hepatitis B vaccine and hepatitis B immunoglobulin for neonates is a safe and effective measure to prevent mother-to-child transmission of HBV.Although combined immunization is performed, infants born to HBeAg-positive mothers still have a rate of chronic HBV infection of 5%-10%. Changes in the immune system during pregnancy can increase the replication of HBV, and the activation of the immune system postpartum can lead to liver function fluctuation and aggravation of chronic hepatitis B patients. Immune failure in infants becomes the main cause of chronic hepatitis B in children and adults. Therefore, specific detection, intervention, and follow-up measures are worthy of attention and discussion for the special population of women of child-bearing age with chronic HBV infection. This article discusses the management of women of child-bearing age with chronic HBV infection before, during, and after pregnancy, the measures for effective monitoring of pregnant women and infants, and individualized therapy based on disease risk assessment and individual conditions. This article also provides reproductive and health guidance for women with chronic hepatitis B who are ready to give birth.
- hepatitis B, chronic /
- hepatitis b virus /
- pregnancy /
- pregnant women

HTML全文

参考文献(17)

[1] LIANG X, BI S, YANG W, et al. Epi-demiological serosurvey of hepatitis B in China—declining HBV prevalence due to hepatitis B vaccination[J]. Vaccine, 2009, 27 (47) :6550-6557.

[2] NI YH, CHANG MH, HUANG LM, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area:15 years after mass hepatitis B vaccination[J]. Ann Intern Med, 2001, 135 (9) :796-800.

[3] ZHANG L, XU A, YAN B, et al. A significant reduction in hepatitis B virus infection among the children of Shandong Province, China:The effect of 15 years of universal infant hepatitis B vaccination[J]. Int J Infect Dis, 2010, 14 (6) :e483-e488.

[4] LAI CL, RATZIU V, YUEN MF, et al. Viral hepatitis B[J]. Lancet, 2003, 362 (9401) :2089-2094.

[5] JONAS MM. Hepatitis B and pregnancy:An underestimated issue[J]. Liver Int, 2009, 29 (Suppl 1) :133-139.

[6] HAN GR, XU CL, ZHAO W, et al. Management of chronic hepatitis B in pregnancy[J]. World J Gastroenterol, 2012, 18 (33) :4517-4521.

[7] PETERSEN J. HBV treatment and pregnancy[J]. J Hepatol, 2011, 55 (6) :1171-1173.

[8] HAN GR, CAO MK, ZHAO W, et al. A prospective and open label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection[J]. J Hepatol, 2011, 55 (6) :1215-1221.

[9] ZHANG H, PAN CALVIN Q, PANG QM, et al. Telbivudine or lamivudineuse in late pregnancy safely reduces perinatal transmission of hepatitis B virus in real-lifepractice[J]. Hepatology, 2014, 60 (2) :468-476.

[10] DIENSTAG JL, SCHIFF ER, WRIGHT TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States[J].N Engl J Med, 1999, 341 (17) :1256-1263.

[11] MAST EE, MARGOLIS HS, FIORE AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States:Recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1:immunization of infants, children, and adolescents[J]. MMWR Recomm Rep, 2005, 54 (RR-16) :1-31.

[12] PAN CQ, HAN GR, JIANG HX, et al. Telbivudine prevents vertical transmission from HBe Ag-positive women with chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2012, 10 (5) :520-526.

[13] GANE EJ, DERAY G, LIAW YF, et al. Telbivudine improves renal function in patients with hepatitis B[J]. Gastroenterology, 2014, 146 (1) :138-146. e5.

[14] SUN J, XIE Q, TAN D, et al. The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients:A randomized, controlled study[J].Hepatology, 2014, 59 (4) :1283-1292.

[15] HAN GR, JIANG HX, YUE X, et al. Efficacy and safety of telbivudine treatment:An open-label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection[J]. J Viral Hepat, 2015, 22 (9) :754-762.

[16] HAN GR, JIANG HX, WANG CM, et al. Long-term safety and efficacy of telbivudine in infants born to mothers treated during the second or third trimesters of pregnancy[J]. J Viral Hepat, 2017, 24 (6) :514-521.

[17] PAN CQ, DUAN Z, DAI E, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load[J]. N Engl J Med, 2016, 374 (24) :2324-2334.

施引文献

资源附件(0)

访问统计